NeurologyBiogen
Biogen and Eisai Present Real-World Evidence for Leqembi in Early Alzheimer's Disease
BMI
Biotechnology Media Insights
Editorial Team · April 15, 2025
Biogen and Eisai share real-world data from CLARITY AD extension study showing lecanemab maintains clinical benefits in early Alzheimer's disease patients.
Biogen and Eisai today presented real-world evidence from the open-label extension of the CLARITY AD trial showing that Leqembi (lecanemab-irmb) maintains clinical benefits in patients with early Alzheimer's disease over 36 months of treatment.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.